INSUBCONTINENT EXCLUSIVE:
NewLimit, a startup that aims to increase how long people can live a healthy life by genetically programming their cells, has raised a $130
million Series B led by Kleiner Perkins.New investors Nat Friedman, Daniel Gross, and Khosla Ventures also invested, as did returning
backers Founders Fund, Dimension Capital, Elad Gil, Garry Tan, Patrick Collison, and others
The fundraise comes two years after the company raised a $40 million Series A.Founded over four years ago by Coinbase CEO Brian Armstrong
(pictured above), former GV partner Blake Byers, and stem cell professor Jacob Kimmel, NewLimit claims it has made significant progress
toward developing treatments that can restore youthful characteristics to aged cells.Kimmel told A Technology NewsRoom the company has
discovered three prototype medicines that reprogram liver cells
measures its progress by contrasting how cells from a younger individual and an older person respond to the substances
results notwithstanding, NewLimit is still a few years away from starting human trials.In the meantime, the company wants to continue
developing new anti-aging medicine using an AI model and then testing the most promising of these machine-generated drugs in its laboratory
eventBerkeley, CA|June 5BOOK NOWOther noteworthy biotech startups developing drugs that aim to increase lifespan include Retro Biosciences,
which raised $180 million from OpenAI CEO Sam Altman two years ago and is reportedly raising a $1 billion Series A; and Altos Labs,
